Diastolic blood pressure (office/clinic)

Method

Diastolic blood pressure taken at a clinic visit with the participant seated after a stated rest period, by auscultatory or validated automated cuff sphygmomanometer, averaged across the readings of that visit.

The method is part of the endpoint identity. Studies measuring the same quantity by a different method are held as separate endpoints.

Notes

Systolic blood pressure (office/clinic) is the same cuff inflation and the same visit, and the two routinely dissociate in both directions: PMID 41388744 found a significant systolic reduction (-2.69 mmHg) with a frankly null diastolic effect, PMID 41515249 the same asymmetry, and PMID 41305552 the reverse, with diastolic the only significant component. Dietary nitrate in particular lowers systolic and not diastolic, so averaging them into 'blood pressure' halves a real signal and can null it. Also distinct from diastolic blood pressure (setting unspecified), whose acquisition protocol is unrecoverable, and from mean arterial pressure, which is weighted towards this component but is not it.

Findings

1 finding from 1 compound, strongest first.

• resveratrol — no detected effect on

  CSuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull result

  “Data analyzed using the multivariate ANOVA model revealed that resveratrol’s effects on systolic and diastolic blood pressure were not statistically significant compared with placebo (Table  3).”

  Study

  crossover

  Participants

  16

  Duration

  4 weeks

  Dose

  500 mg twice daily, oral

  Population

  pre-hypertensive and stage-1 hypertensive adults aged 20-60 years, Iran; primary outcome; 2 x 2 crossover, 16 completers analysed

  Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients.2025PMID:40854984